Crossref
Revisiting the Low-Dose Aspirin Benefit-Risk Discussion in the Context of New Risk Assessment Tools
Federal Practitioner · 03.11.2026 · 43 (Suppl 5)
DOI: 10.12788/fp.0778 ↗Kurz gefasst
Fachartikel in der Zeitschrift Federal Practitioner, online erschienen am 03.11.2026. Verfasst von Steven Weisman.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Weisman, S. (2026). Revisiting the Low-Dose Aspirin Benefit-Risk Discussion in the Context of New Risk Assessment Tools. Federal Practitioner, 43(Suppl 5). https://doi.org/10.12788/fp.0778
Vancouver
Weisman S. Revisiting the Low-Dose Aspirin Benefit-Risk Discussion in the Context of New Risk Assessment Tools. Federal Practitioner. 2026;43(Suppl 5). doi:10.12788/fp.0778
BibTeX
@article{Weisman2026,
author = {Weisman, Steven},
title = {Revisiting the Low-Dose Aspirin Benefit-Risk Discussion in the Context of New Risk Assessment Tools},
journal = {Federal Practitioner},
year = {2026},
volume = {43},
number = {Suppl 5},
doi = {10.12788/fp.0778}
}
EUVIMED